mdi-2517
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 17, 2024 (NCT06453824)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Plasminogen activator inhibitor-1INHIBITOR
SERPINE1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07220889 | Phase 1 | Nov 4, 2025 | MDI Therapeutics, Inc. |
| NCT06453824 | Phase 1 | May 17, 2024 | MDI Therapeutics, Inc., Syneos Health |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MDI Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2024 |
| Syneos Health | For profit | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1